NeuroSense Therapeutics Ltd. (NRSN)

NASDAQ: NRSN · IEX Real-Time Price · USD
1.210
+0.010 (0.83%)
At close: May 17, 2024, 4:00 PM
1.180
-0.030 (-2.48%)
After-hours: May 17, 2024, 5:07 PM EDT
0.83%
Market Cap 20.80M
Revenue (ttm) n/a
Net Income (ttm) -11.28M
Shares Out 17.33M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 78,589
Open 1.200
Previous Close 1.200
Day's Range 1.160 - 1.285
52-Week Range 0.400 - 2.330
Beta 1.71
Analysts Strong Buy
Price Target 7.50 (+519.84%)
Earnings Date May 30, 2024

About NRSN

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under pr... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 9, 2021
Employees 18
Stock Exchange NASDAQ
Ticker Symbol NRSN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for NRSN stock is "Strong Buy" and the 12-month stock price forecast is $7.5.

Price Target
$7.5
(519.84% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

PhaseV's Causal Machine Learning Predicts High Probability of Success in Multiple ALS Subgroups for NeuroSense's Phase 3 Trial CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- NeuroSense Therapeutics (...

4 days ago - PRNewsWire

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patients Consistent data across subgroups underscore the potential of PrimeC to redefine the ALS treatment paradigm CAM...

11 days ago - PRNewsWire

NeuroSense Announces First Quarter 2024 Business Update

CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

16 days ago - PRNewsWire

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

CAMBRIDGE, Mass. , April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

26 days ago - PRNewsWire

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consistent trend toward impact on Neurofilament biomarker levels CAMBRIDGE, Mass....

4 weeks ago - PRNewsWire

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

Emerging Science (Late-Breaker Equivalent) Abstract To Be Presented At 5:30PM Local Time Highlights Phase 2 PARADIGM Outcomes CAMBRIDGE, Mass. , April 12, 2024 /PRNewswire/ -- NeuroSense Therapeutics ...

5 weeks ago - PRNewsWire

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

CAMBRIDGE, Mass. , April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

5 weeks ago - PRNewsWire

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field Lonza to develop, optimize, and qualify a method util...

5 weeks ago - PRNewsWire

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

CAMBRIDGE, Mass. , April 5, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

6 weeks ago - PRNewsWire

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS Standard ALS Measure ALSFRS-R already demonstrated a statistically signifi...

3 months ago - PRNewsWire

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

CAMBRIDGE, Mass. , Feb. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

3 months ago - PRNewsWire

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

HERZLIYA, ISRAEL / ACCESSWIRE / January 30, 2024 / Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. I...

Other symbols: BIIB
3 months ago - Accesswire

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership discussions CAMBRIDGE, Mass. , ...

4 months ago - PRNewsWire

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

This notification has no immediate effect on the listing or trading of NeuroSense's ordinary shares on the Nasdaq Capital Market CAMBRIDGE, Mass. , Dec. 27, 2023 /PRNewswire/ -- NeuroSense Therapeutic...

5 months ago - PRNewsWire

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

A  statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol (PP) populat...

5 months ago - PRNewsWire

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense's lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints with a safe...

5 months ago - PRNewsWire

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

Data to be announced in a premarket press release followed by a conference call at 8:30 am ET CAMBRIDGE, Mass. , Dec. 4, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

5 months ago - PRNewsWire

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial (PARADIGM) expected in early December 2023 Patients who completed the 18-month PARADIGM trial, includin...

6 months ago - PRNewsWire

NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness

Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

6 months ago - PRNewsWire

NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences

- Last patient completed the double-blind segment of PARADIGM, a Phase 2b ALS Trial - Clinical efficacy top-line results from PARADIGM expected in December 2023 CAMBRIDGE, Mass. , Nov. 9, 2023 /PRNews...

6 months ago - PRNewsWire

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

Clinical efficacy results ( s econdary endpoints) and safety results (primary endpoints) expected December 2023 Biogen collaboration biomarker results expected Q1 2024 Primary biomarker endpoints to b...

6 months ago - PRNewsWire

NeuroSense Therapeutics to Participate in BIO-Europe Fall

CAMBRIDGE, Mass. , Nov. 1, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

7 months ago - PRNewsWire

Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics' Lead Drug Candidate, PrimeC

HERZLIYA, ISRAEL / ACCESSWIRE / October 19, 2023 / Induced pluripotent stem cells (iPSCs) have emerged as a promising tool in the field of research and therapy for neurodegenerative diseases such as A...

7 months ago - Accesswire

NeuroSense CEO Provides Q3 2023 Update

Phase 2b ALS topline results expected December 2023 CAMBRIDGE, Mass. , Oct. 17, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

7 months ago - PRNewsWire

NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model

In collaboration with the University of Southern California's Ichida Stem Cell Lab, PrimeC was shown to significantly increase survival rate of induced motor neurons in an in vitro study utilizing ind...

8 months ago - PRNewsWire